Generex Biotechnology Corp. (fka GNBTQ)

[Scootter82]

Not sure how this will look. I think there were supposed to be charts in there too.......



Generex Biotechnology Corporation (Generex) is a development-stage company. The Company is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company is focused on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through its wholly owned subsidiary, Antigen Express, Inc. (Antigen), the Company has expanded its focus to include immunomedicines incorporating vaccine formulations. The Company's subsidiaries include Generex Pharmaceuticals Inc., Generex (Bermuda), Inc., Generex Pharmaceuticals (USA) LLC and Generex Marketing & Distribution Inc. In April 1999, the Company completed a reorganization in which it merged with Generex Idaho. In September 2009, the Company announced the incorporation of SIA Generex Biotechnology BALTIC as a wholly owned subsidiary.

Valuation Ratios
Price/Earnings (TTM) --
Price/Sales (TTM) 234.41x
Price/Book (MRQ) 5.96x
Price/Cash Flow (TTM) --
TTM = Trailing Twelve Months MRQ = Most Recent Quarter

Price Performance
Advanced Charts

Price Change





Price Performance Since 2005
Mouse over year for more details
Historic Growth and Share Detail
Historic Growth

Short Interest

Share Information
Annual Growth, Past 5 Years

December 2009 December 2009

GNBT is in a share class of CS
EPS

NM

Current Month
4.0M 3.9M 3.9M

Float
243.9M
Revenue

12.28%

Previous Month
4.0M 3.9M 3.9M

Shares Outstanding
248.5M
Dividend
No Regular Dividend is paid

Percent of Float
1.57% 1.58%

Institutions Holding Shares
26

Days to Cover
1 Days 1 Days 1.9558 Days

Held By Institutions (MRQ)
3.21%

Financial Statements
Balance Sheet

Values above are in thousands.
Income Statement

Values above are in thousands.
Cash Flow Statement

Values above are in thousands.


Company Officers
Anna E Gluskin Chmn., Dir.
Rose C Perri CFO, COO
Mark Fletcher Exec.VP, Counsel
Gerald Bernstein VP
Address
33 Harbour Square
Toronto, ON M5J 2G2
Canada
Phone: [phone]
Fax: [phone]
http://www.generex.com/
Insider Trading Activity
Over the last six months, 49K shares were bought, and 53K shares were sold in insider trading.